

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
Date of first issue: 19.03.2021

SECTION 1. IDENTIFICATION

Product name : Oxfendazole / Oxyclozanide Formulation

Manufacturer or supplier's details

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, Testis, Brain)
repeated exposure

Short-term (acute) aquatic : Category 1
hazard

Long-term (chronic) aquatic : Category 1
hazard

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if
swallowed.

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.
 H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements

Prevention:
 P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P260 Do not breathe dust.
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
 P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
 P391 Collect spillage.

Storage:
 P405 Store locked up.

Disposal:
 P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
 Contact with dust can cause mechanical irritation or drying of the skin.
 May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Oxyclozanide	2277-92-1	>= 30 -< 50
oxfendazole	53716-50-0	>= 20 -< 25
Starch, oxidized	65996-62-5	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.0	30.09.2023	7942485-00007	Date of first issue: 19.03.2021

- of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : May damage fertility. May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
-

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Chlorine compounds
Nitrogen oxides (NO_x)
Metal oxides
Oxides of phosphorus
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency measures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	CMP (inhalable dust)	0,5 mg/m ³	AR OEL
	Further information: Sensitization			
		TWA (inhalable dust)	0,5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	CMP	10 mg/m ³	AR OEL
	Further information: A4 - Not classifiable as a human carcinogen			
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.0	30.09.2023	7942485-00007	Date of first issue: 19.03.2021

- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection** : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance** : powder
- Color** : white to off-white, light cream, cream
- Odor** : No data available
- Odor Threshold** : No data available
- pH** : No data available
- Melting point/freezing point** : No data available
- Initial boiling point and boiling range** : No data available
- Flash point** : Not applicable
- Evaporation rate** : Not applicable
- Flammability (solid, gas)** : May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids)** : Not applicable
- Upper explosion limit / Upper flammability limit** : No data available
- Lower explosion limit / Lower flammability limit** : No data available
- Vapor pressure** : Not applicable
- Relative vapor density** : Not applicable

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
Date of first issue: 19.03.2021

Relative density : No data available

Density : 0,88 g/cm³

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
Date of first issue: 19.03.2021

Components:**Oxyclozanide:**

Acute oral toxicity : LD50 (Rat): 3.519 mg/kg
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg

LD50 (Dog): 1.600 mg/kg

LD50 (sheep): 250 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Oxyclozanide:**

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Oxyclozanide:**

Remarks : Not classified due to lack of data.

Oxfendazole / Oxcyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

oxfendazole:

Species : Rabbit
 Result : No eye irritation

Magnesium stearate:

Species : Rabbit
 Result : No eye irritation
 Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Oxcyclozanide:**

Routes of exposure : Dermal
 Remarks : Not classified due to lack of data.

Magnesium stearate:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative
 Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Oxcyclozanide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: Chromosomal aberration
 Test system: Human lymphocytes
 Result: positive

Test Type: Mouse Lymphoma
 Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Mouse
 Application Route: Oral
 Result: negative

Test Type: unscheduled DNA synthesis assay

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

Species: Rat
 Cell type: Liver cells
 Application Route: Oral
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Species: Mouse
 Application Route: Oral
 Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Oxyclozanide:**

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
 Application Route : Oral
 Exposure time : 1 Years
 Symptoms : No adverse effects.
 Target Organs : Liver

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 Symptoms : No adverse effects.
 Target Organs : Liver

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
Date of first issue: 19.03.2021

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Oxyclozanide:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects., No effects on fertility.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity., Skeletal malformations.

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, male
 Application Route: Oral
 Fertility: NOAEL: 17 mg/kg body weight
 Target Organs: Testes
 Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 0,9 mg/kg body weight
 Target Organs: Liver
 Result: No effects on fertility.

Test Type: Fertility
 Species: Mouse
 Application Route: Oral
 Duration of Single Treatment: 1 Months
 Fertility: NOAEL: 750 mg/kg body weight
 Target Organs: Testes
 Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 10 mg/kg body weight
 Result: positive, Fetal effects.

Test Type: Embryo-fetal development
 Species: Rat
 Developmental Toxicity: NOAEL: 10 mg/kg body weight
 Result: positive, Embryo-fetal toxicity.

Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Oral
 Developmental Toxicity: NOAEL: 108 mg/kg body weight
 Result: positive, Embryo-fetal toxicity., Fetal abnormalities.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 0,625 mg/kg body weight

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

Oxfendazole / Oxylozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

reproduction/developmental toxicity screening test
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 422
 Result: negative
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:**Oxylozanide:**

Routes of exposure : Oral
 Target Organs : Central nervous system
 Assessment : May cause damage to organs.

STOT-repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:**Oxylozanide:**

Target Organs : Brain, Liver
 Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure : Oral
 Target Organs : Liver, Testis
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Oxylozanide:**

Species : Rat
 NOAEL : 9 mg/kg
 LOAEL : 44,5 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Brain, Liver, spleen, Adrenal gland
 Symptoms : Liver effects

Species : Dog

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

NOAEL : 5 mg/kg
 LOAEL : 25 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Brain, Liver
 Symptoms : blood effects, alteration in liver enzymes

oxfendazole:

Species : Rat
 NOAEL : 11 mg/kg
 Application Route : Oral
 Exposure time : 2 Weeks
 Target Organs : Blood, Liver, Testis

Species : Rat
 NOAEL : 3,8 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Liver, Testis

Species : Mouse
 NOAEL : 750 mg/kg
 Application Route : Oral
 Exposure time : 1 Months
 Target Organs : Liver

Species : Mouse
 NOAEL : 37,5 mg/kg
 Application Route : Oral
 Exposure time : 3 Months
 Target Organs : Liver

Species : Dog
 NOAEL : 6 mg/kg
 Application Route : Oral
 Exposure time : 1 Months
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 11 mg/kg
 Application Route : Oral
 Exposure time : 2 Weeks
 Target Organs : Lymph nodes, thymus gland

Species : Dog
 NOAEL : 13,5 mg/kg
 Application Route : Oral
 Exposure time : 12 Months
 Target Organs : Liver

Starch, oxidized:

Species : Rat
 NOAEL : 22.500 mg/kg
 Application Route : Ingestion

Oxfendazole / Oxyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

Exposure time : 90 Days

Magnesium stearate:

Species : Rat
 NOAEL : > 100 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Oxyclozanide:**

Not applicable

Experience with human exposure**Components:****Oxyclozanide:**

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,69 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

M-Factor (Acute aquatic toxicity) : 1

M-Factor (Chronic aquatic toxicity) : 1

oxfendazole:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2,7 mg/l
 Exposure time: 96 h
 LC50 (Oncorhynchus mykiss (rainbow trout)): > 2,5 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,059 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l

Oxfendazole / Oxyκλοzanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

	Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0,023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 1

Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.
	NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability**Components:****Oxyκλοzanide:**

Oxfendazole / Oxcyclozanide Formulation

Version 3.0 Revision Date: 30.09.2023 SDS Number: 7942485-00007 Date of last issue: 04.04.2023
 Date of first issue: 19.03.2021

Stability in water : Hydrolysis: 50 %(156 d)
 Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
 Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Oxcyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3,99
 pH: 7
 Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1,95

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Oxcyclozanide:**

Distribution among environmental compartments : log Koc: 4,83
 Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3,2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
 Dispose of in accordance with local regulations.
 Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
 If not otherwise specified: Dispose of as unused product.

Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.0	30.09.2023	7942485-00007	Date of first issue: 19.03.2021

preparation of drugs.

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	30.09.2023
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.0	30.09.2023	7942485-00007	Date of first issue: 19.03.2021

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8